Analyst Reco. Viridian Therapeutics, Inc.

Equities

VRDN

US92790C1045

Market Closed - Nasdaq Other stock markets 01:30:00 26/06/2024 am IST			5-day change	1st Jan Change
12.76 ^USD	-3.41%		+4.76%	-41.41%

11/06	Sector Update: Health Care Stocks Mixed Premarket Tuesday	MT
11/06	Sector Update: Health Care	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Wolfe Research Initiates Coverage on Viridian Therapeutics With Outperform Rating, $29 Price Target	11/06	MT
Goldman Sachs Initiates Coverage on Viridian Therapeutics With Buy Rating, $23 Price Target	06/06	MT
Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating	09/05	MT
B. Riley Downgrades Viridian Therapeutics to Neutral From Buy	09/05	MT
B. Riley Downgrades Viridian Therapeutics to Neutral From Buy, Cuts Price Target to $20 From $25	09/05	MT
Wedbush Raises Viridian Therapeutics Price Target to $42 From $40, Maintains Outperform Rating	08/05	MT
B. Riley Lowers Viridian Therapeutics' PT to $25 From $29, Keeps Buy Rating; Adjusts Model to Reflect Recent Equity Offering, Quarterly Numbers	21/03	MT
Wedbush Lifts Viridian Therapeutics' PT to $40 From $39 on Higher Net Cash, Keeps Outperform Rating	28/02	MT
Wedbush Trims Viridian Therapeutics' Price Target to $39 From $40, Keeps Outperform Rating	22/01	MT
Oppenheimer Raises Viridian Therapeutics Price Target to $36 From $35, Maintains Outperform Rating	19/12	MT
Wedbush Raises Viridian Therapeutics' PT to $40 From $37, Keeps Outperform Rating; Says Remains Among a Top Pick Into 2024	19/12	MT
JMP Securities Adjusts Price Target on Viridian Therapeutics to $38 From $42, Maintains Market Outperform Rating	14/11	MT
B. Riley Lowers Viridian Therapeutics' PT to $29 From $46 to Reflect Dilutive Financing, Lower Peak Sales in TED; Maintains Buy Rating	14/11	MT
RBC Cuts Price Target on Viridian Therapeutics to $35 From $44, Keeps Outperform Rating, Speculative Risk Qualifier	31/23/31	MT
Wedbush Lowers Viridian Therapeutics' PT to $37 From $46 on Heels of Leadership Changes, Private Placement; Keeps Outperform Rating	31/23/31	MT
HC Wainwright Adjusts Price Target on Viridian Therapeutics to $37 From $40, Keeps Buy Rating	10/23/10	MT
Needham Adjusts Price Target on Viridian Therapeutics to $40 From $47, Keeps Buy Rating	10/23/10	MT
Oppenheimer Adjusts Viridian Therapeutics Price Target to $35 From $40, Maintains Outperform Rating	09/23/09	MT
Wells Fargo Adjusts Price Target on Viridian Therapeutics to $39 From $46, Maintains Overweight Rating	09/23/09	MT
Wedbush Lifts Viridian Therapeutics' PT to $46 From $45 After Adjusting Share Count Assumptions, Keeps Outperform Rating	09/23/09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Viridian Therapeutics, Inc.

Equities

VRDN

US92790C1045

Analyst Reco.

Filters